Overall, there is a growing body of evidence demonstrating that PSMA can provide effective staging for prostate cancer, guide targeted biopsies of highly active lesions, and detect MRI-occult lesions, and that a high SUVMax is associated with adverse pathological features, which would make a patient unsuitable for active surveillance. Here, FOLH1 is linked to prostate carcinoma.